InvestSMART

Cogstate Limited (ASX: CGS) - Announcements

Current share price for CGS : $2.770 0.03 (1.07%)+

ASX company news and announcements for Cogstate Limited (CGS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cogstate Limited (CGS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cogstate Limited (CGS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cogstate Limited (CGS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$472 Business Update 21 Jan 2013 9:58AM $0.350 $2.775 risen by 692.86%
$472 Chairman & CEO's AGM speech 16 Oct 2012 12:41PM $0.400 $2.775 risen by 593.75%
$472 CogState tests helping to detect Alzheimer's disease 16 Oct 2012 9:05AM $0.400 $2.775 risen by 593.75%
$472 Appendix 4C - quarterly 12 Oct 2012 12:27PM $0.350 $2.775 risen by 692.86%
$472 CogState signs sales contract for phase 3 study 12 Oct 2012 12:25PM $0.350 $2.775 risen by 692.86%
$472 Preliminary Final Report 21 Aug 2012 3:58PM $0.270 $2.775 risen by 927.78%
$472 Appendix 4C - quarterly 27 Jul 2012 12:48PM $0.250 $2.775 risen by 1,010%
$472 Business update 12 Jul 2012 10:01AM $0.290 $2.775 risen by 856.90%
$472 CogState partners with Merck Canada 25 Jun 2012 9:20AM $0.300 $2.775 risen by 825%
$472 Appendix 4C - quarterly 26 Apr 2012 12:18PM $0.320 $2.775 risen by 767.19%
$472 Half Yearly Report and Accounts 21 Feb 2012 1:46PM $0.270 $2.775 risen by 927.78%
$472 Appendix 4C - quarterly 25 Jan 2012 3:06PM $0.250 $2.775 risen by 1,010%
$472 CogState Signs Contract For Phase 2 Schizophrenia Study 8 Dec 2011 11:24AM $0.240 $2.775 risen by 1,056.25%
$472 CogState signs sales contract for phase 2 study 22 Nov 2011 10:46AM $0.255 $2.775 risen by 988.24%
$472 CogState signs sales contract for large phase 2 study 16 Nov 2011 11:46AM $0.245 $2.775 risen by 1,032.65%
$472 Appendix 4C - quarterly 25 Oct 2011 1:01PM $0.190 $2.775 risen by 1,360.53%
$472 Growth in sales contracts delivers strong Q1 results 13 Oct 2011 2:52PM $0.160 $2.775 risen by 1,634.38%
$472 CogState signs sales contract for phase 3 study 25 Aug 2011 9:58AM $0.170 $2.775 risen by 1,532.35%
$472 Preliminary Final Report 23 Aug 2011 5:09PM $0.160 $2.775 risen by 1,634.38%
$472 CogState Acquires 100% Holding of Axon Sports 22 Aug 2011 9:42AM $0.170 $2.775 risen by 1,532.35%
$472 Business Update 29 Jul 2011 1:45PM $0.170 $2.775 risen by 1,532.35%
$472 Appendix 4C - quarterly 22 Jul 2011 9:32AM $0.165 $2.775 risen by 1,581.82%
$472 Business Update - Unaudited Full Year Profit Results 22 Jul 2011 9:31AM $0.165 $2.775 risen by 1,581.82%
$472 CogState signs sales contract for large phase 2 study 23 May 2011 9:40AM $0.200 $2.775 risen by 1,287.50%
$472 CogState announces partnership in area of cognitive training 19 May 2011 12:30PM $0.200 $2.775 risen by 1,287.50%

876 - 900 of 992 results

Page 36 of 40

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.